Omaha, Nebraska 68198


The purpose of this study is to compare the efficacy of oral N-acetylcysteine and intravenous sodium bicarbonate for the prevention of CIN after cardiac catheterization.

Study summary:

It is thought that N-acetylcysteine may reduce the ability of generated oxygen free radicals to damage cells by scavenging them. N-acetylcysteine may also increase the biologic effects of nitric oxide by combining with nitric oxide to form S-nitrosothiol, a more stable form and potent vasodilator. It also increases the expression of nitric oxide synthesis and may improve blood flow. Oxidants activate a signal-transduction cascade and molecular response that may initiate the cell-death pathway. These pathways seem to be sensitive to the redox state of the cell and are inhibited by N-acetylcysteine, which promotes pathways that lead to repair and survival whenever cells are under oxidant stress.


Inclusion Criteria: 19 years of age - Baseline serum creatinine or - Calculated creatinine - Stable Renal Function - Left Ventricular ejection fraction - Non-pregnant, non-lactating females (all women of childbearing potential must have a negative serum pregnancy test. No contraception will be required - Able to sign informed consent Exclusion Criteria: - Acute renal failure - History of Kidney transplant - Currently receiving N-acetylcysteine _ Contraindication of hypersensitivity to N-acetylcysteine or sodium bicarbonate - Left ventricular ejection fraction - Pregnant, lactating females - Allergy to contrast dye

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:


Brief Title:

A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate

Official Title:

A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization

Overall Status:


Study Phase:




Minimum Age:

19 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

University of Nebraska

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Intervention Model: Para

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Scott Shurmur, MD
Principal Investigator
University of Nebraska

Study Dates

Start Date:May 2005
Completion Date:January 2011
Completion Type:Anticipated
Primary Completion Date:January 2011
Primary Completion Type:Anticipated
Verification Date:June 2010
Last Changed Date:June 25, 2010
First Received Date:December 18, 2007

Study Outcomes

Outcome Type:Primary Outcome
Measure:to compare the effectiveness of two medications, oral N-acetylcysteine (mucomyst) and intravenous sodium bicarbonate, used to protect the kidneys from contrast injury during a cardiac catheterization
Time Frame:2 years
Safety Issues:True

Study Interventions

Intervention Type:Drug
Name:Oral N-Acetylcysteine
Description:600 mg
Arm Name:1, oral N-Acetylcysteine
Other Name:NAC
Intervention Type:Drug
Name:Intravenous Sodium Bicarbonate
Description:3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
Arm Name:2, Intravenous Sodium Bicarbonate
Other Name:Sodium hydrogen carbonate

Study Arms

Study Arm Type:No Intervention
Arm Name:1, oral N-Acetylcysteine
Study Arm Type:No Intervention
Arm Name:2, Intravenous Sodium Bicarbonate

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of Nebraska

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.